Data from BioTime’s Renevia® Program to Be Presented at IFATS Conference
November 30 2017 - 7:00AM
Business Wire
BioTime, Inc. (NYSE American: BTX), a late-stage, clinical
biotechnology company developing and commercializing products
addressing degenerative diseases, today announced that detailed
data from the successful pivotal trial of Renevia® in Europe will
be presented at the International Federation Adipose
Therapeutics and Science (IFATS) conference on November 30, 2017.
The Renevia® program will be presented by primary investigator
Ramon Llull, MD, PhD, Director of Stem Europe Mallorca Center,
Mallorca, Spain at the “Plenary Session 2 - Clinical Studies with
SVF”.
About Renevia®
Renevia® is an investigational medical device that is being
developed as an alternative for whole adipose tissue transfer (fat
grafting) procedures. Renevia’s® hydrogel polymer network
provides the requisite amino acid sequences for adipose stromal
vascular cell attachment and may support proliferation,
localization and adipogenic differentiation. Renevia® is part
of the Hystem® hydrogel family of proprietary injectable matrices,
which are designed to facilitate the survival and growth of
transplanted cells.
About BioTime, Inc.
BioTime is a late stage clinical biotechnology company
focused on developing and commercializing products addressing
degenerative diseases. The Company’s current clinical programs are
targeting three primary sectors, aesthetics, ophthalmology and cell
and drug delivery. Its clinical programs are based on two platform
technologies: pluripotent cells, which can become any type of cell
in the human body, and cell/drug delivery. Renevia®, a cell
delivery product, met its primary endpoint in an EU pivotal
clinical trial for the treatment of facial lipoatrophy in HIV
patients earlier this year. Submission for approval of
Renevia® in the EU is expected to be early 2018, with possible
approval and commercial launch in 2018. There were no device
related serious adverse events reported. OpRegen®, a retinal
pigment epithelium transplant therapy, is in a Phase I/IIa
multicenter trial for the treatment of dry age-related macular
degeneration, the leading cause of blindness in developing
countries. There were no related serious adverse events
reported. BioTime also has significant equity holdings in
two publicly traded companies, Asterias Biotherapeutics,
Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE
American: OCX), and a private company, AgeX Therapeutics,
Inc.
BioTime common stock is traded on the NYSE American and
TASE under the symbol BTX. For more information, please
visit www.biotime.com or connect with the company
on Twitter, LinkedIn, Facebook, YouTube,
and Google+.
To receive ongoing BioTime corporate communications,
please click on the following link to join the Company’s email
alert list: http://news.biotime.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171130005347/en/
Investor Contact:BioTimeDavid Nakasone,
510-871-4188Dnakasone@biotime.comorMedia Contact:JQA
Partners, Inc.Jules Abraham,
917-885-7378jabraham@jqapartners.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Apr 2023 to Apr 2024